Episode Details

In the latest TDR Cannabis in Five presented by Flowhub, Shadd Dales takes a step back and looks at what just happened over the past week—and why it matters.Because this wasn’t just another policy update.Between cannabis rescheduling and a new executive order on psychedelic research, we’re seeing one of the most meaningful shifts in U.S. drug policy in decades.On the cannabis side, the Department of Justice has now formally moved state-licensed medical marijuana to Schedule III. That opens the door to expanded research and, importantly for operators, potential relief from 280E.At the same time, the Trump administration signed an executive order aimed at accelerating psychedelic research—fast-tracking clinical trials and expanding access for treatments targeting PTSD, depression, and other serious conditions.In this episode, we break down:

• What actually changed this week on cannabis rescheduling
• What the psychedelic executive order means in practical terms
• Why both of these moves are happening now
• And how this starts to shift the broader conversation around healthcare and treatment

This doesn’t solve everything. There are still gaps across regulation, banking, and federal law.But the direction is becoming clearer.And that’s what matters.#CannabisNews #CannabisRescheduling #Psychedelics #Healthcare #ScheduleIII #TradeToBlack #Flowhub #CannabisPolicy #MedicalCannabis #InvestingWant to see more Cannabis Reform?🎬    • White House Says Cannabis Is Popular | TDR...  🎬    • DEA Applications Now Open — Clock Started ...  🎬    • What Cannabis Rescheduling Actually Means ...  🎬    • Cannabis Rescheduling Is Now Official | TD...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:

Listen Now